We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.
The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...
Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback